Stryker (SYK) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Executive summary
Definitive additional proxy materials have been filed in accordance with SEC regulations, indicating an upcoming shareholder meeting or vote.
No filing fee was required for this submission, as specified in the filing details.
Voting matters and shareholder proposals
The filing relates to proxy materials soliciting shareholder votes, as indicated by the Schedule 14A submission.
Shareholder rights and capital structure
The document references securities transactions and the potential for shareholder voting on such matters, though no specific transaction details are provided.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Stryker
- Virtual meeting to elect directors, ratify auditor, and approve pay amid strong 2025 results.SYK
Proxy filing23 Mar 2026 - Strategy targets digital, M&A, and margin gains, with double-digit EPS growth through 2028.SYK
Investor Day 20253 Feb 2026 - Q2 organic sales up 9%, adjusted EPS up 10.6%, and guidance raised on strong demand.SYK
Q2 20242 Feb 2026 - Double-digit growth, record Mako installs, and strong 2026 outlook despite tariff headwinds.SYK
Q4 20252 Feb 2026 - Mako innovation, easing pricing, and new launches drive growth and share gains into 2025.SYK
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook and M&A momentum.SYK
Q3 202418 Jan 2026 - Double-digit organic growth and margin expansion, with portfolio moves and Spine impairments.SYK
Q4 20249 Jan 2026 - Double-digit sales growth, innovation, and all proposals approved amid leadership transitions.SYK
AGM 20258 Jan 2026 - 2025 targets 8%-9% growth, margin expansion, and innovation through ASC, robotics, and M&A.SYK
Citi’s 2025 Medtech and Life Sciences Access Day7 Jan 2026